NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) announced that scientists at Enzo Therapeutics today reported data from preclinical animal studies on a small molecule compound that could serve as an attractive non-hormonal therapeutic agent for prevention of periodontal bone loss.
Their findings were presented at the annual meeting of the American Society of Bone Mineral Research (ASBMR) in Honolulu, Hawaii. The abstract, entitled, “Small Organic Molecule Compound Protects Against Inflammatory Bone Loss in a Rat Model of Periodontitis,” was authored by Enzo scientists as well as their collaborators.
